信立泰：信超妥等药品被新纳入国家医保目录

Core Viewpoint - The company, Sinopharm, has successfully negotiated the inclusion of its drugs in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance market access and sales potential for these products [1] Group 1: Drug Inclusion in Insurance List - The drugs Xinchaotuo (Sacubitril/Valsartan) and Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) have been newly included in the Class B category of the insurance list [1] - The drug Ennaruo (Entresto) has successfully renewed its contract to remain in the insurance list [1] - The drug Xinlitai (Aliskiren Tablets) has been adjusted to regular management under the insurance directory [1] Group 2: Previous Negotiations - The drugs Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) and Xinliting (Bempedoic Acid Tablets) were previously included in the insurance list through negotiations and are still under valid agreements, classified under Class B [1]